Author

Andreas Feichtner

Universität InnsbruckORCID 0000-0002-9376-6229Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Assay:protein sequence· 1 Assay:proteomics· 1 Approach:statistical model· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

Eduard StefaniD· 2 shared Bruce Randall DonaldiD· 1 shared Christian L. Heine· 1 shared Christina S. Moesslacher· 1 shared Elisabeth AuernigiD· 1 shared Evelyne Jany-LuigiD· 1 shared Jonathan WoodsmithiD· 1 shared Josephine M. Worseck· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersSystems Biology

Eduard StefanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Missense variant interaction scanning reveals a critical role of the FERM-F3 domain for tumor suppressor protein NF2 conformation and function

Christina S. Moesslacher, Jonathan Woodsmith, Elisabeth Auernig, Andreas Feichtner, Evelyne Jany-Luig, Stefanie Jehle, Josephine M. Worseck, Christian L. Heine, Eduard Stefan, Ulrich Stelzl

The paper identifies missense variants in NF2 that affect its conformation and tumor suppressor function through systematic mutational interaction perturbation analysis.

Life Science Alliance · Jun 6, 2023Peer-reviewedSystems Biology

Resistor: an algorithm for predicting resistance mutations using Pareto optimization over multistate protein design and mutational signatures

Nathan Guerin, Andreas Feichtner, Eduard Stefan, Teresa Kaserer, Bruce Randall Donald

RO_SCPLOWESISTORC_SCPLOW predicts resistance mutations by optimizing four criteria using Pareto frontiers, identifying clinically relevant mutations in EGFR and BRAF inhibitors.

bioRxiv · Jan 18, 2022 · PreprintBioinformatics